GILEAD SCIENCES, INC.

Key metrics

Financial performance

Over the last 9 fiscal years GILEAD SCIENCES, INC.'s revenue declined from $30.39B to $29.44B, a compound annual decline rate of 0.4%. Net profit margin compressed from 44.4% to 28.9% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (968 filings)

Recent press releases

• FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)2026-05-22

  **_–_ _Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death_ _–_**

• Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors2026-05-22

  **_– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients–_**

• Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease2026-05-21

  **_\- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year -_**

• Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio2026-05-21

  – **_Acquisition Builds on Gilead’s Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform_**–

• New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology2026-05-21

  **_– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches –_**

Similar companies

The largest companies sharing GILEAD SCIENCES, INC.'s SEC industry classification (biological products, (no diagnostic substances)).